Acta Neuropathologica

, Volume 115, Issue 4, pp 427–436 | Cite as

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

  • Kurt A. JellingerEmail author
  • Johannes Attems
Original Paper


Whereas the prevalence and impact of vascular pathology in Alzheimer diease (AD) are well established, the role of vascular and Alzheimer pathologies in the progression of neurodegeneration and cognitive impairment in Parkinson disease (PD) is under discussion. A retrospective clinico-pathologic study of 100 patients with autopsy proven PD (including 44 cases with dementia/PDD) and 20 cases of dementia with Lewy bodies (DLB) confirmed essential clinical (duration of illness, Mini-Mental State Examination/MMSE, age at death) and morphologic differences between these groups; Lewy body Braak scores and Alzheimer pathologies (neuritic Braak stage, cortical Aβ plaque load, and generalized cerebral amyloid angiopathy or CAA) were significantly higher/more severe in DLB and PDD than in PD without dementia. Duration of illness showed no association to any of the examined pathologic parameters, while there was a moderate association between LB scores and neuritic Braak stages, the latter significantly increasing with age. Significant association between cerebrovascular lesions and neuritic Braak stage was seen in PDD but not in PD subjects without dementia. These data suggest an influence of Alzheimer-related lesions on the progression of the neurodegenerative process and, in particular, on cognitive decline in both PDD and DLB. On the other hand, both these factors in PD and DLB appear to be largely independent from coexistent vascular pathology, except in cases with severe cerebrovascular lesions or those related to neuritic AD pathology. Assessment of ApoE genotype in a small number of cases showed no significant differences in the severity of Aβ plaque load and CAA except for much lower intensities in non-demented ε3/3 patients. Despite increasing evidence suggesting synergistic reactions between α-synuclein (αSyn), tau and Aβ-peptides, the major protein markers of both AD and Lewy body diseases, and of both vascular pathology and AD, the molecular background and pathophysiological impact of these pathologies on the progression of neurodegeneration and development of cognitive decline in PD await further elucidation.


Lewy body disease Alzheimer-related pathology Cerebrovascular lesions Clinico-pathologic relations Parkinson disease with dementia 



The authors are indebted to the colleagues of the clinical departments and Institute of Pathology of OWS Hospital (head: Prof. Dr. F. Lintner), Vienna, Austria, for the clinical and pathological data and the brain material; to Mrs. Veronika Rappelsberger for excellent laboratory work, and to Mr. Erich Mitter-Ferstl, Ph.D., for secretarial work. The study was supported in part by the Society for the Support of Research in Experimental Neurology, Vienna, Austria.


  1. 1.
    Adler CH, Grover AC, Sabbagh MN, Caviness JN, Connor DJ, Beach TG (2006) Clinical and pathologic findings in PD with LRRK2 mutations: 2 cases with mild cognitive impairment and small amplitude myoclonus. Mov Disord 21(Suppl 15):S538Google Scholar
  2. 2.
    Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888:287–296PubMedCrossRefGoogle Scholar
  3. 3.
    Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110:345–359PubMedCrossRefGoogle Scholar
  4. 4.
    Attems J, Jellinger KA, Lintner F (2005) Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 110:222–231PubMedCrossRefGoogle Scholar
  5. 5.
    Attems J, Quass M, Jellinger KA, Lintner F (2007) Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci 257:49–55PubMedCrossRefGoogle Scholar
  6. 6.
    Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 26:573–578PubMedCrossRefGoogle Scholar
  7. 7.
    Bancher C, Egensperger R, Kosel S, Jellinger K, Graeber MB (1997) Low prevalence of apolipoprotein E epsilon 4 allele in the neurofibrillary tangle predominant form of senile dementia. Acta Neuropathol 94:403–409PubMedCrossRefGoogle Scholar
  8. 8.
    Barrachina M, Dalfo E, Puig B, Vidal N, Freixes M, Castano E, Ferrer I (2005) Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem Int 46:253–260PubMedCrossRefGoogle Scholar
  9. 9.
    Bertrand E, Lewandowska E, Pasennik E, Stepien T, Szpak GM, Dymecki J, Wierzba-Bobrowicz T (2007) Cerebral amyloid angiopathy in idiopathic Parkinson’s disease. Acta Neuropathol (in press)Google Scholar
  10. 10.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRefGoogle Scholar
  11. 11.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  12. 12.
    Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134PubMedCrossRefGoogle Scholar
  13. 13.
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMedGoogle Scholar
  14. 14.
    Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051PubMedCrossRefGoogle Scholar
  15. 15.
    Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT (2004) Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 127:791–800PubMedCrossRefGoogle Scholar
  16. 16.
    Burton EJ, McKeith IG, Burn DJ, Firbank MJ, O’Brien JT (2006) Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 14:842–849PubMedCrossRefGoogle Scholar
  17. 17.
    Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA (2003) Parkinson’s disease is associated with hippocampal atrophy. Mov Disord 18:784–790PubMedCrossRefGoogle Scholar
  18. 18.
    de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152–1162CrossRefGoogle Scholar
  19. 19.
    Del Ser T, Hachinski V, Merskey H, Munoz DG (2001) Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 15:31–44PubMedCrossRefGoogle Scholar
  20. 20.
    Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65:278–288PubMedGoogle Scholar
  21. 21.
    Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood–brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant 16:285–299PubMedGoogle Scholar
  22. 22.
    Dickson DW (2000) Alzheimer–Parkinson disease overlap: neuropathology. In: Clark CM, Trojanowski JQ (eds) Neurodegenerative dementias. McGraw-Hill, New York, pp 247–259Google Scholar
  23. 23.
    Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20:2302–2312PubMedCrossRefGoogle Scholar
  24. 24.
    Galasko D, Salmon D (2000) The Alzheimer–Parkinson’s disease connection. In: Clark CM, Trojanowski JQ (eds) Neurodegenerative dementias. McGraw-Hill, New York, pp 229–246Google Scholar
  25. 25.
    Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedCrossRefGoogle Scholar
  26. 26.
    Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67:1605–1611PubMedCrossRefGoogle Scholar
  27. 27.
    Geddes JW (2005) Alpha-synuclein: a potent inducer of tau pathology. Exp Neurol 192:244–250PubMedCrossRefGoogle Scholar
  28. 28.
    Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640PubMedCrossRefGoogle Scholar
  29. 29.
    Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59:315–322PubMedCrossRefGoogle Scholar
  30. 30.
    Greenberg SM, Gurol ME, Rosand J, Smith EE (2004) Amyloid angiopathy-related vascular cognitive impairment. Stroke 35:2616–2619PubMedCrossRefGoogle Scholar
  31. 31.
    Guerini F, Frisoni GB, Bellwald C, Rossi R, Bellelli G, Trabucchi M (2004) Subcortical vascular lesions predict functional recovery after rehabilitation in patients with l-dopa refractory parkinsonism. J Am Geriatr Soc 52:252–256PubMedCrossRefGoogle Scholar
  32. 32.
    Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384PubMedCrossRefGoogle Scholar
  33. 33.
    Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMedGoogle Scholar
  34. 34.
    Hansen LA (1997) The Lewy body variant of Alzheimer disease. J Neural Transm Suppl 51:83–93PubMedGoogle Scholar
  35. 35.
    Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP (2005) The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol Scand 112:386–390PubMedCrossRefGoogle Scholar
  36. 36.
    Hughes TA, Ross HF, Mindham RH, Spokes EG (2004) Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 110:118–123PubMedCrossRefGoogle Scholar
  37. 37.
    Iseki E, Marui W, Kosaka K, Ueda K (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 265:9–12PubMedCrossRefGoogle Scholar
  38. 38.
    Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 105:265–270PubMedGoogle Scholar
  39. 39.
    Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMedGoogle Scholar
  40. 40.
    Jellinger KA (1996) Parkinsonism due to Binswanger’s subcortical arteriosclerotic encephalopathy. Mov Disord 11:461–462PubMedCrossRefGoogle Scholar
  41. 41.
    Jellinger KA (2003) Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm 110:771–778PubMedCrossRefGoogle Scholar
  42. 42.
    Jellinger KA (2003) Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study. Acta Neuropathol 105:415–419PubMedGoogle Scholar
  43. 43.
    Jellinger KA, Attems J (2003) Incidence of cerebrovascular lesions in Alzheimer’s disease: a postmortem study. Acta Neuropathol 105:14–17PubMedGoogle Scholar
  44. 44.
    Jellinger KA, Mitter-Ferstl E (2003) The impact of cerebrovascular lesions in Alzheimer disease––a comparative autopsy study. J Neurol 250:1050–1055PubMedCrossRefGoogle Scholar
  45. 45.
    Jellinger KA, Seppi K, Wenning GK (2003) Neuropathologic changes in Parkinson disease with late onset of dementia. Arch Neurol 60:452–453 author reply 453–454CrossRefGoogle Scholar
  46. 46.
    Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMedCrossRefGoogle Scholar
  47. 47.
    Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229–230:37–41PubMedCrossRefGoogle Scholar
  48. 48.
    Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson’s disease. J Neurol Sci 248:167–172PubMedCrossRefGoogle Scholar
  49. 49.
    Jellinger KA, Attems J (2006) Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism. Acta Neurol Scand 114:38–46PubMedCrossRefGoogle Scholar
  50. 50.
    Jellinger KA (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113:349–388PubMedCrossRefGoogle Scholar
  51. 51.
    Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257:80–87PubMedCrossRefGoogle Scholar
  52. 52.
    Jellinger KA, Attems J (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm. doi: 10.1007/S00702-00007.00856.00708
  53. 53.
    Jendroska K, Lees AJ, Poewe W, Daniel SE (1996) Amyloid beta-peptide and the dementia of Parkinson’s disease. Mov Disord 11:647–653PubMedCrossRefGoogle Scholar
  54. 54.
    Junque C, Ramirez-Ruiz B, Tolosa E, Summerfield C, Marti MJ, Pastor P, Gomez-Anson B, Mercader JM (2005) Amygdalar and hippocampal MRI volumetric reductions in Parkinson’s disease with dementia. Mov Disord 20:540–544PubMedCrossRefGoogle Scholar
  55. 55.
    Kallhoff V, Peethumnongsin E, Zheng H (2007) Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer’s disease. Mol Neurodegener 2:6PubMedCrossRefGoogle Scholar
  56. 56.
    Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128PubMedCrossRefGoogle Scholar
  57. 57.
    Kumaran R, Kingsbury A, Coulter I, Lashley T, Williams D, de Silva R, Mann D, Revesz T, Lees A, Bandopadhyay R (2007) DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiol Dis 28:122–132PubMedCrossRefGoogle Scholar
  58. 58.
    Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T (2008) Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol. doi: 10.1007/s00401-00007-00336-00400
  59. 59.
    Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52:33–38PubMedCrossRefGoogle Scholar
  60. 60.
    Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491PubMedCrossRefGoogle Scholar
  61. 61.
    Lippa CF (2004) Synaptophysin immunoreactivity in Pick’s disease: comparison with Alzheimer’s disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 19:341–344PubMedCrossRefGoogle Scholar
  62. 62.
    Lippa SM, Lippa CF, Mori H (2005) Alpha-Synuclein aggregation in pathological aging and Alzheimer’s disease: the impact of beta-amyloid plaque level. Am J Alzheimers Dis Other Demen 20:315–318PubMedCrossRefGoogle Scholar
  63. 63.
    Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31:1153–1162PubMedCrossRefGoogle Scholar
  64. 64.
    Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (2003) The role of alpha-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci 4:727–738PubMedCrossRefGoogle Scholar
  65. 65.
    Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC (1995) Binswanger’s disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord 10:450–454PubMedCrossRefGoogle Scholar
  66. 66.
    Marshall GA, Shchelchkov E, Kaufer DI, Ivanco LS, Bohnen NI (2006) White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand 113:87–91PubMedCrossRefGoogle Scholar
  67. 67.
    Marti MJ, Tolosa E, de la Cerda A (2007) Dementia in Parkinson’s disease. J Neurol 254(Suppl):41–48CrossRefGoogle Scholar
  68. 68.
    Marui W, Iseki E, Ueda K, Kosaka K (2000) Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease. J Neurol Sci 174:81–84PubMedCrossRefGoogle Scholar
  69. 69.
    Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98:12245–12250PubMedCrossRefGoogle Scholar
  70. 70.
    Mastaglia FL, Masters CL, Beyreuther K, Kakulas BA (1989) Deposition of Alzheimer’s disease amyloid (A4) protein in the cerebral cortex in Parkinson’s disease. Prog Clin Biol Res 317:475–484PubMedGoogle Scholar
  71. 71.
    Mastaglia FL, Johnsen RD, Kakulas BA (2002) Prevalence of stroke in Parkinson’s disease: a postmortem study. Mov Disord 17:772–774PubMedCrossRefGoogle Scholar
  72. 72.
    Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA (2003) Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 18:81–86PubMedCrossRefGoogle Scholar
  73. 73.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  74. 74.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  75. 75.
    Mikolaenko I, Pletnikova O, Kawas CH, O’Brien R, Resnick SM, Crain B, Troncoso JC (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64:156–162PubMedGoogle Scholar
  76. 76.
    Mrak RE, Griffin WS (2007) Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 66:683–686PubMedGoogle Scholar
  77. 77.
    Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, Dagher A, Ito K (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64:224–229PubMedGoogle Scholar
  78. 78.
    Neumann M, Muller V, Gorner K, Kretzschmar HA, Haass C, Kahle PJ (2004) Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol 107:489–496PubMedCrossRefGoogle Scholar
  79. 79.
    Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47:190–196PubMedGoogle Scholar
  80. 80.
    Olichney JM, Ellis RJ, Katzman R, Sabbagh MN, Hansen L (1997) Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann N Y Acad Sci 826:493–497PubMedCrossRefGoogle Scholar
  81. 81.
    Papapetropoulos S, Lieberman A, Gonzalez J, Mash DC (2005) Can Alzheimer’s type pathology influence the clinical phenotype of Parkinson’s disease? Acta Neurol Scand 111:353–359PubMedCrossRefGoogle Scholar
  82. 82.
    Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMedGoogle Scholar
  83. 83.
    Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192PubMedCrossRefGoogle Scholar
  84. 84.
    Popescu A, Lippa CF, Lee VM, Trojanowski JQ (2004) Lewy bodies in the amygdala: increase of a-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 61:1915–1919PubMedCrossRefGoogle Scholar
  85. 85.
    Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN (1996) Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol 148:2083–2095PubMedGoogle Scholar
  86. 86.
    Reitz C, Trenkwalder C, Kretzschmar K, Roesler A, Eckardstein VA, Berger K (2006) Relation of cerebral small-vessel disease and brain atrophy to mild Parkinsonism in the elderly. Mov Disord 21(11):1914–1919PubMedCrossRefGoogle Scholar
  87. 87.
    Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246PubMedGoogle Scholar
  88. 88.
    Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMedGoogle Scholar
  89. 89.
    Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S (2004) Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63:742–749PubMedGoogle Scholar
  90. 90.
    Schmidt ML, Martin JA, Lee VM, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders. Acta Neuropathol 91:475–481PubMedCrossRefGoogle Scholar
  91. 91.
    Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS (2006) Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J Neuropathol Exp Neurol 65:327–335PubMedCrossRefGoogle Scholar
  92. 92.
    Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733–748PubMedGoogle Scholar
  93. 93.
    Thanvi B, Lo N, Robinson T (2005) Vascular parkinsonism––an important cause of parkinsonism in older people. Age Ageing 34:114–119PubMedCrossRefGoogle Scholar
  94. 94.
    Thomas A, Ballard C, Kenny RA, O’Brien J, Oakley A, Kalaria R (2005) Correlation of entorhinal amyloid with memory in Alzheimer’s and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 19:57–60PubMedCrossRefGoogle Scholar
  95. 95.
    Tian J, Shi J, Mann DM (2004) Cerebral amyloid angiopathy and dementia. Panminerva Med 46:253–264PubMedGoogle Scholar
  96. 96.
    Trembath D, Ervin JF, Broom L, Szymanski M, Welsh-Bohmer K, Pieper C, Hulette CM (2007) The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype. Acta Neuropathol 113:23–31PubMedCrossRefGoogle Scholar
  97. 97.
    Trembath Y, Rosenberg C, Ervin JF, Schmechel DE, Gaskell P, Pericak-Vance M, Vance J, Hulette CM (2003) Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease. Acta Neuropathol 105:484–488PubMedGoogle Scholar
  98. 98.
    Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMedGoogle Scholar
  99. 99.
    Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362PubMedCrossRefGoogle Scholar
  100. 100.
    Wirths O, Bayer TA (2003) Alpha-synuclein, Abeta and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 27:103–108PubMedCrossRefGoogle Scholar
  101. 101.
    Wu E, Lipton RB, Dickson DW (1992) Amyloid angiopathy in diffuse Lewy body disease. Neurology 42:2131–2135PubMedGoogle Scholar
  102. 102.
    Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607PubMedCrossRefGoogle Scholar
  103. 103.
    Zlokovic BV (2004) Clearing amyloid through the blood–brain barrier. J Neurochem 89:807–811PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Institute of Clinical NeurobiologyViennaAustria
  2. 2.Division of Neuropathology, Institute of PathologyOWS HospitalViennaAustria

Personalised recommendations